Opinion
Video
Author(s):
David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.
Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy
FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma
Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer
Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48
Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized
Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC